NASDAQ:STTK

Shattuck Labs Stock News

Healthcare > Biotechnology

Buy STTK

*Your capital is at risk

$7.92

+0.630 (+8.64%)

At Close: Aug 04, 2026

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

06:30am, Tuesday, 26'th Aug 2025

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune dis

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

10:17am, Thursday, 21'st Aug 2025

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

06:30am, Thursday, 14'th Aug 2025

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

06:30am, Tuesday, 05'th Aug 2025

– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

07:00am, Wednesday, 02'nd Jul 2025

AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

04:20pm, Thursday, 01'st May 2025

– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

05:00pm, Wednesday, 02'nd Apr 2025

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor ne

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

07:00am, Thursday, 27'th Mar 2025

– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-c

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

09:00am, Thursday, 20'th Feb 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate t

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

04:30pm, Thursday, 13'th Feb 2025

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necro

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by